Comparing of Regeneron Pharmaceuticals Inc. (REGN) and ImmunoGen Inc. (NASDAQ:IMGN)

As Biotechnology companies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ImmunoGen Inc. (NASDAQ:IMGN) are our subject to compare. And more specifically their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 6.71B 6.62 2.44B 18.46 20.46
ImmunoGen Inc. 53.82M 16.04 167.87M -1.03 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Regeneron Pharmaceuticals Inc. and ImmunoGen Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 36.36% 25.9% 18.5%
ImmunoGen Inc. -311.91% -684.8% -43.8%

Volatility & Risk

Regeneron Pharmaceuticals Inc. has a beta of 1.34 and its 34.00% more volatile than Standard & Poor’s 500. ImmunoGen Inc.’s 153.00% more volatile than Standard & Poor’s 500 which is a result of the 2.53 beta.

Liquidity

The Current Ratio and a Quick Ratio of Regeneron Pharmaceuticals Inc. are 4 and 3.6. Competitively, ImmunoGen Inc. has 4.6 and 4.6 for Current and Quick Ratio. ImmunoGen Inc.’s better ability to pay short and long-term obligations than Regeneron Pharmaceuticals Inc.

Analyst Ratings

In next table is shown Regeneron Pharmaceuticals Inc. and ImmunoGen Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 3 2 2.40
ImmunoGen Inc. 0 0 0 0.00

Regeneron Pharmaceuticals Inc.’s upside potential currently stands at 0.94% and an $412.33 consensus target price.

Insider and Institutional Ownership

Roughly 73.7% of Regeneron Pharmaceuticals Inc. shares are held by institutional investors while 85.6% of ImmunoGen Inc. are owned by institutional investors. Insiders held roughly 0.4% of Regeneron Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 0.1% of ImmunoGen Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 3.27% 3.66% -4.42% 21.04% 1.07% 0.43%
ImmunoGen Inc. -2.36% -12.8% -43.19% -43.49% -11.07% -16.07%

For the past year Regeneron Pharmaceuticals Inc. had bullish trend while ImmunoGen Inc. had bearish trend.

Summary

Regeneron Pharmaceuticals Inc. beats on 10 of the 12 factors ImmunoGen Inc.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.